The mega-threat of the microscopic soybean cyst nematode (SCN) looms large over U.S. soybean fields. SCN’s insatiable appetite for soybean roots makes it the No. 1 yield-reducing soybean pest ...

Weeds in soybean fields are doing more than competing for resources like nutrients and water. More than 100 common weed species are hosts, creating refuge for soybean cyst nematode populations and ...

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic cancer Getty Daraxonrasib targets a previously untreatable protein in ...

An experimental drug that could be a breakthrough in the treatment of one of the deadliest known cancers is driving demand at clinics while awaiting full government approval. Daraxonrasib, a drug that ...

Get unlimited access to ad-free articles and exclusive content. An AI model developed at the Mayo Clinic in Rochester, Minnesota, detected abnormalities on patients’ CT scans up to three years before ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.” Daraxonrasib, an ...

When former Nebraska Sen. Ben Sasse was diagnosed with Stage 4 pancreatic cancer in December, he was given three to four months to live. Now a drug by Revolution Medicines is giving him precious more ...

An experimental treatment has doubled one-year survival rates for pancreatic cancer, one of the deadliest types of cancer, a new study reports. The drug, called elraglusib, targets the protective web ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more ...